Presented recommendations are an extended and actualized version of paediatric recommendations of Polish Society of Hypertension published in 2015. Since then, new studies have appeared on this subject, introducing a new classification of hypertension, newly described principles of management in risk groups and methods of assessing hypertensive target organ damage. The presented updated recommendations included changes introduced in the 2016 European Society of Hypertension recommendations and Recommendations of Children's Memorial Health Institute in Warsaw. Recently published guidelines of American Academy of Pediatrics have been discussed. In the presented issue of guidelines, epidemiological information on the occurrence and incidence of hypertension in developmental age was added and classification of blood pressure values was updated. Subchapters on diagnosis and organ damage assessment, principles of diagnosis and treatment of hypertension in children with diabetes, chronic kidney disease and a subsection discussing diagnostic and therapeutic difficulties with setting blood pressure targets were revised. In addition, the principles of early diagnosis of arterial hypertension in post-hospital care in children born before 33 weeks of gestation published in 2018 as recommendations of the Polish Neonatal Society have been also taken into account.
Introduction
Arterial hypertension (AH) is one of the main potentially modifiable cardiovascular risk factors. It is also one of the main clinical problems of adult medicine, and it is one of the most common chronic diseases in adolescents. In addition to the primary form of hypertension (essential hypertension), AH is an important complication of other chronic diseases such as: type 1 diabetes mellitus (T1DM), type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD), www.ah.viamedica.pl coarctation of the aorta, congenital adrenal hyperplasia and others.
Because T2DM is relatively rare in Caucasian children and adolescents, children with overweight and obesity, especially those with carbohydrate intolerance and insulin resistance, should be treated as a potential risk group for AH. Arterial hypertension is also increasingly important in children and adults born prematurely, especially before 33 weeks of gestation and in children born with intrauterine hypotrophy (small for gestational age, SGA) [1] [2] [3] .
These guidelines are an extended and actualized version of paediatric guidelines of the Polish Society of Hypertension published in 2015 and presented in the extended version as Recommendations of the Children's Memorial Health Institute in 2016 [4] . This version of paediatric recommendations of the Polish Society of Hypertension was developed on the basis of the previously published recommendations of the Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents (The 4 th Report), the paediatric recommendations of the European Society of Hypertension (ESH) published in 2009 and 2016, the recommendations of the Children's Memorial Health Institute (2016), the recommendations of the European Society of Cardiology (ESC)/American Heart Association (AHA) (2017), the recommendations of the American Academy of Pediatrics (AAP) (2017), literature review and expert opinions [5] [6] [7] [8] .
Compared to paediatric 2015 Guidelines of the Polish Society of Hypertension, this version contains more epidemiological information on the prevalence and incidence of AH at developmental age, expanded or modified subchapters on diagnostics and assessment of organ damage, AH in children with diabetes and CKD, and a subchapter discussing diagnostic and therapeutic difficulties. New subchapter has been added describing the principles of early diagnostics of AH in post-hospital care of children born before the 33 weeks of pregnancy, which were published in the 2018 guidelines of the Polish Neonatal Society. An important novelty is the new classification of AH presented earlier in the 2016 ESH Guidelines and recommendations of the Children's Memorial Health Institute published in 2016.
The new subchapter discusses problems with setting blood pressure targets. The chapter on the principles of blood pressure measurement gives new recommendations on how to measure blood pressure in newborns, infants and young children. References has been updated and expanded.
Epidemiology of hypertension in children and adolescents
Data from representative population studies indicate that hypertension is present in 3-5% of children and adolescents aged 0-18 years. In the OLAF and OLA studies, conducted in representative population samples, BP values above the 95 th percentile for age and gender, calculated as the mean of the second and third BP measurement during a single visit, were found in 6.9% of children aged 3-6 years, 7.7% of children aged 6-10 years, and 6.2% of youths aged 10-20 years [6] .
The prevalence of AH in Polish adolescents aged 14-18 years (in 18-year-olds AH was diagnosed according to the definition for adults, i.e. as the blood pressure value ≥ 140/90 mmHg) reaches the values found in young adults aged 20-30 years, i.e. 10-13% [9] [10] [11] . From puberty and on, AH is 3-4 times more frequent in boys than in girls. This proportion is observed up to the 5 th decade of life and is associated with physiological pressure increase during puberty in boys. In risk groups, such as patients with obesity, CKD, T1DM and T2DM, the prevalence of AH is much higher and ranges from 5-25% (T1DM) to 30-40% (T2DM). The group of particularly high risk of AH development is prematurity and low birth weight. Estimates indicate that AH was diagnosed at the age of 3 in 7.3% of prematurely born children. The risk of developing AH increases with a younger gestational age and is particularly high in those born before 33 weeks of pregnancy [12] .
Secondary hypertension is the major cause of hypertension in younger children. With increasing rates of obesity in children and adolescents, the proportion of primary hypertension increases and it is diagnosed in about 50% of all children evaluated due to hypertension.
www.ah.viamedica.pl related to health problems. In children below 3 years of age, BP measurement is recommended in selected cases in children with identified health problems (Table I) [5, 13] . Screening for hypertension in children below 24 months of age is not supported by society guidelines and epidemiological study findings [14] . BP measurements in younger children are at a high risk of failure due to lack of patient cooperation: the proportion of unreliable BP measurements is 41% in children at one year of age, 20% in children aged 3 years, and 9% of children aged 3-6 years.
diagnosis of hypertension

Definitions and classification of hypertension in children and adolescents
According to the generally accepted definition of hypertension in children, this diagnosis requires BP readings ≥ 95 th percentile for age, gender, and height during three separate visits. The literature also uses the term "elevated blood pressure", which refers to children who have a blood pressure value greater than 95 th percentile only on one occasion, which does not allow the diagnosis of AH. The meaning of the term "elevated blood pressure" changed when the 2017 AAP guidelines adopted this term to describe the value of arterial blood pressure in the range previously referred to as prehypertension.
Classification of hypertension in children and adolescents depends on the method of BP measurement.
Due to discrepancies in the interpretation of arterial blood pressure in adolescents (see below), in youths aged ≥ 16 years it is recommended to use the same classification as in adults. Based on office measurements (using the auscultatory or oscillometric method), the following categories are distinguished:
• Normal BP Table I . Blood pressure measurements in children and adolescents -indications and technique
• BP should be measured in all children aged ≥ 3 years at least once a year and during any routine physician examination.
• BP measurement is more reliable if the child has not eaten a meal within 30 minutes before the measurement, has not received medications that might affect BP, and has been resting in a sitting position with its back supported in a quiet environment for 5-10 minutes before the measurement.
• During the initial consultation, BP should be measured on all four limbs. During the first year of life and until the child assumes the upright position, BP readings in the lower limbs are lower than in the upper limbs. During the second year of life in a child who stands/walks, BP readings in the lower limbs are higher by about 20 mmHg, and at a later age they are higher by about 30-40 mmHg.
• Subsequent measurements should be performed on the right arm that is fully exposed, abducted and supported at the level of the heart.
• The cuff should encircle the full circumference of the arm and cover at least 40% of its length. The inflatable bladder should encircle at least 80% of the arm circumference, including the whole medial aspect of the arm. A measurement performed using a cuff that is too narrow may overestimate BP by as much as 30%, and underestimate BP if the cuff is too wide.
• In infants, the body position has no significant effect on BP values. During sleep, SBP values in infants are lower by 5-7 mmHg.
• As readings obtained during the first measurement are usually overestimated, in such cases BP should be measured 2-3 times on one occasion.
• BP readings above the 90 th percentile by the oscillometric method require verification by the auscultatory method.
• If the BP difference between the upper limbs is ≥ 5 mmHg, this fact should be noted in the medical record.
• In younger children (< 3 years), BP should be measured in the following situations: -perinatal morbidity: prematurity, low birth weight, perinatal intensive therapy; -congenital anomalies; -recurrent urinary tract infections, other renal and/or urinary tract disease; -cancer; -solid organ or bone marrow transplantation; -use of drugs affecting BP; -symptoms and conditions associated with hypertension (neurofibromatosis, tuberous sclerosis, others), increased intracranial pressure.
www.ah.viamedica.pl (Table II) . In the classification of hypertension in children that was adopted in both European and U.S. guidelines, categories of severe hypertension and hypertensive urgencies and emergencies have not been defined. However, the following definitions of these conditions are used for practical purposes [15, 16] 
Reference blood pressure values
Reference values for office measurements
It is recommended to use reference BP values for a given age, gender and height developed for specific BP measurement methods (auscultatory, oscillometric). For BP measurements using the auscultatory method, the most commonly used are reference www.ah.viamedica.pl [18] . For oscillometric (automated) BP measurements reference values developed for the Polish population of children aged 3-18 years are recommended [9] . Due to the fact that in paediatric practice the most commonly used measurement method is automatic measurement, these standards have been included in the "new" Child Health Record Book (2016).
Home blood pressure measurements
In children with the diagnosis of hypertension, home BP measurements (HBPM) using a validated oscillometric device are recommended (https:// nadcisnienietetnicze.pl/ptnt/wytyczne_ptnt). Use of the reference values developed by Stergiou et al. for children and adolescents aged 6-18 years is recommended (Table IV) [19, 21] . No reference BP values were developed for HBPM in younger children. Evaluation based on BP measurements twice daily during at least 3 days is considered reliable, and the optimal approach involves morning and evening BP measurements performed during 7 subsequent days. It is recommended to perform 2-3 measurements at short intervals and to record the value of the last measurement. The optimal assessment is based on morning and evening measurements performed in the consecutive 7 days. Adequate home BP measurements are considered a reliable indicator of the effectiveness of antihypertensive therapy [20] .
Ambulatory 24-hour blood pressure monitoring
Ambulatory BP monitoring (ABPM) using a validated oscillometric device is recommended in all children above 5 years of age and higher than 119 cm in whom hypertension was diagnosed based on office BP measurements. The reference BP values for ABPM developed by Wühl et al. and adopted in the 2014 AHA guidelines should be used, and in adolescents > 16 years of age -reference values for adults. Routine repeated ABPM is recommended to evaluate treatment effects [17] .
Principles of blood pressure measurement
The technique for measuring blood pressure is presented in Table I . For routine measurements, automatic (oscillometric) and auscultatory measurements can be used, and if elevated BP is detected by an automatic method, it should be confirmed by auscultatory BP measurement. Other rules apply to newborns and young children, in whom the auscultatory measurement is technically difficult and associated with a larger white-apron effect than the automatic (oscillometric) measurement. In this age group (up to 3-4 years of age) it is recommended to perform multiple automatic measurements in short intervals. In addition, in neonates and small infants who have indication for blood pressure measurement, it is recommended to perform measurements according to the protocol described in the section "Arterial hypertension in the newborn" (Table XVIII) . th percentile in girls aged 18 years. Another phenomenon concerning adolescents is isolated systolic AH observed especially in boys without significant additional risk factors, often practicing sports. In these cases, the so-called spurious hypertension should be taken into account in which elevated systolic blood pressure is found only on the peripheral arteries, e.g. on the brachial artery, while the central pressure is normal. There are also no signs of organ damage in these cases. Therefore, when interpreting BP values, consideration should also be given to exposure to cardiovascular risk factors (intermediate phenotype) and the presence of subclinical organ damage (see below).
As most currently used ABPM devices are based on the oscillometric method, it should be emphasized that with this method, the mean arterial pressure (MAP) is directly evaluated, and SBP and DBP values are calculated using appropriate algorithms. In addition, results of some controlled paediatric studies (e.g., the ESCAPE study) and therapeutic recommendations are based on the analysis of MAP values. Another interpretation issue related to ABPM is the fact that using this method, higher BP values comparted to office measurements are obtained in children below 10 years of age and those with the height below 120 cm. Due to lacking reference values and the above mentioned interpretation issues, routine use of ABPM is not recommended in children below 5 years of age.
On the other hand, in tall children and adolescents 95 th percentile values may exceed the reference range adopted for adults. The mentioned problems were the reason for the change in the definition and classification of AH in adolescents aged ≥ 16 years old (see Diagnosis of hypertension). th percentile range. While non-pharmacological treatment is not a problem, it should be considered whether to implement pharmacological treatment in patients with persistent high normal pressure despite non-pharmacological treatment. Thus, it would also be logical to change the definition of AH.
Problems
Indirect evidence that blood pressure targets for children with primary AH and without other conditions should be set at 90 th percentile provide results of studies performed in adult hypertensive patients, especially SPRINT [21] and published in 2016 meta-analysis of trials assessing the effectiveness of antihypertensive treatment in risk groups such as patients with CKD and diabetes [22] . The analysis of the results of Cardiovascular Risk in Young Finns Study provides arguments for both modifying the definition of AH in children and changing the threshold of blood pressure target values to 90 th percentile. The study showed significantly higher blood pressure and higher arterial stiffness, assessed as the pulse wave velocity, in adult patients who had high normal blood pressure values (i.e. between 90 th and 95 th percentile) in childhood and adolescence compared with those who in childhood and adolescence had blood pressure below 90 th percentile [23] . In the AAP [24] recommendations published in 2017, based on the results of the SPRINT study, new AH definitions were proposed. Lower blood pressure targets (below 90 th percentile or below 130/80 mmHg) were also recommended in children with primary AH, arguing that lowering blood pressure below these values leads to a further reduction in left www.ah.viamedica.pl ventricular hypertrophy. It should be noted, however, that the SPRINT study examined the population of patients with mean age of 67 years who were previously treated with antihypertensive drugs and were already burdened with additional diseases. Moreover, the blood pressure measurement method was different from that used in clinical practice. Also, the papers cited in the AAP guidelines do not report further reduction of left ventricular mass in children whose blood pressure was lowered below 90 th percentile [25] . It should also be noted that in children and adolescents with primary AH the strongest predictor of the reduction of left ventricular mass and the incidence of left ventricular hypertrophy is not a decrease in blood pressure values, but visceral fat reduction, expressed as waist circumference reduction, and normalization of metabolic disorders [26] . Taking the above into consideration, in the presented guidelines for children and adolescents with primary AH and without additional diseases, we recommend blood pressure levels lower than 95 percentile (or below 140/90 mmHg). At the same time, we recommend intensive non-pharmacological treatment as a basic therapeutic option in primary AH and in children with high-normal BP.
Similar difficulties are related to the diagnosis threshold for AH and recommended target BP values in children with CKD and children with diabetes. In children with CKD, pharmacological treatment is recommended when blood pressure exceeds 90 th percentile, and the target BP values depend on the presence of proteinuria. The current recommendations are based on the results of the ESCAPE study, which showed that in children with proteinuria > 0.5 g/day, a reduction in mean arterial blood pressure in the ABPM measurement below 50 th percentile is beneficial. However, these benefits have not been demonstrated for children with lower proteinuria or no proteinuria. The ESH guidelines and expert position statements (review articles) recommend that in these cases the target pressure values should be below 75 th percentile, although even the papers cited in these documents do not provide any justification for such a recommendation. Nevertheless, because there is strong pathophysiological link between proteinuria, even small, and progression of CKD, we recommend to try to lower BP below 50 th percentile for 24h MAP if it is tolerated, in all patients with CKD. Similar recommendations have been endorsed by AAP.
Methods to evaluate target organ damage
Basic approaches to evaluate the severity of hypertensive target organ damage in children include:
• evaluation of left ventricular mass, systolic function, and diastolic function by echocardiography; • ECG; • fundoscopy;
• evaluation of renal function.
Evaluation of left ventricular mass
Left ventricular mass (LVM) is a major criterion of target organ damage. Echocardiography is the standard method to diagnose left ventricular hypertrophy, and ECG is only an additional diagnostic tool due to its low specificity and the need for age-specific interpretation (nevertheless, it is a study that allows to detect arrhythmias and myocardial ischemia, which is of practical importance, because non-pharmacological treatment based on physical exercise/ /sport is the basic therapy for primary AH). The most commonly used approach to evaluate LVM is based on the recommendations of the American Society of Echocardiography and uses the Deveraux formula. As LVM depends on height, it is recommended to calculate LVM indexed for height in meters to the power of 2.7 according to the formula suggested by de Simone. Published reference values and percentiles of the LVM index calculated using this formula allow using this parameter in children over 1 year of age [27] . A limitation of indexing LVM for height is the possibility to overdiagnose left ventricular hypertrophy in obese children in comparison to indexing for fat-free body weight. Nevertheless, it is currently the most commonly used and recommended (ESH 2009 (ESH , 2016 , the 4 th Report, AAP) approach to evaluate LVM in children and adolescents that allows not only comparisons of echocardiographic findings in children of varying age but also comparing paediatric data with the results obtained in adults. However, due to the introduction of AH classification for adolescents aged ≥ 16 years that is consistent with the definitions used in adults, in this age group of adolescents it is recommended to diagnose left ventricular hypertrophy according to the criteria for adults (see below).
The assessment of left ventricular systolic and diastolic dysfunction is not different from that used in adults. When assessing diastolic function, it should be taking into account early (E) filling wave to atrial (A) wave (E/A) ratio is higher in younger children [28] [29] [30] . The assessment of left ventricular diastolic function based on tissue Doppler examination is increasingly being used and relevant paediatric reference values have been published [31] . The results of this study may be an additional parameter for the assessment of target organ damage. percentile of LVM in children and adolescents [32] .
Fundoscopy
The principles of fundoscopic examination in children do not differ from those in adults. The Keith-Wagener-Barker classification is commonly used in clinical practice. A simplified classification includes 2 types of changes, benign and malignant. Benign changes are Keith-Wagener-Barker grade 1 and/or grade 2 lesions, and malignant changes are grade 3 and/or grade 4 lesions. The simplified classification allows initial patient selection for more or less intensive treatment [30, 32] . Computer analysis of retinal arterial and venous diameter is increasingly used in the assessment of risk of cardiovascular events, including stroke in adults with AH, but still is not commonly used in children with AH [33, 34] . Although the initial assessment of the fundus is relatively simple, in clinical practice, few paediatric hypertension specialists perform fundoscopic examination. Therefore, fundoscopy is suggested as an optional examination in the diagnosis of children and adolescents with asymptomatic AH, but is recommended as a routine diagnostic method in symptomatic AH and hypertension urgency and emergency.
Evaluation of renal damage
Routine methods to evaluate renal function include glomerular filtration rate (GFR) estimation using the Schwartz formula and/or serum cystatine C level measurements. Albuminuria is an indicator of hyperfiltration and/or microvascular damage. There are no commonly accepted reference values for albuminuria in children, and adult cut-off values are used in practice, with albuminuria above 30 mg/24 h corresponding to the 95 th percentile values.
Hyperuricaemia in subjects with normal GFR is considered as an abnormality specific for primary hypertension. However, it is not clear whether increased serum uric acid concentration is a primary phenomenon or occurs secondarily to subclinical renal damage [35, 36] . Clinical trials and population studies show that in adolescents aged 12-17 years, uric acid > 5.5 mg/dl is associated with a 2-fold higher risk of primary hypertension.
Non-obligatory additional tests to evaluate the extent of target organ damage in children and adolescents
Non-obligatory additional tests to evaluate the extent of target organ damage in children and adolescents include: -assessment of carotid intima-media thickness (cIMT); -measurement of the pulse wave velocity (PWV). During the last decade, multiple reports have been published that support using cIMT and PWV measurements to evaluate target organ damage, and pediatric reference values for cIMT and PWV have been published (Table V and VI) [37] [38] [39] [40] [41] [42] . These tests are already recommended (ESH 2016) as additional in the assessment of target organ damage in children with AH. However, the assessment of cIMT and PWV is still performed only in a few centres. Therefore, until these methods are commonly used in clinical practice, we recommend them as non-obligatory.
Principles of the differential diagnosis of hypertension in children and adolescents
Differential diagnosis of hypertension in children includes three steps (Table VII) . The extent of diagnostic investigations depends on the severity of hypertension, patient's age, and concomitant conditions. Indications for more extensive investigations that include diagnostic steps 1 and 2 are younger patient's age (before puberty; an arbitrarily chosen age threshold is 12 years, i.e. below average age of pubertal growth spurt), and/or grade 2 hypertension and/or presence of target organ damage and/ /or concomitant chronic conditions. Diagnostic step 1 includes confirmation of the diagnosis of hypertension, exclusion of white coat hypertension, classification and grading the severity of hypertension, evaluation of target organ damage, and basic laboratory tests to exclude secondary hypertension. Diagnostic step 2 includes tests that usually require hospital admission, but if possible may be done also on outpatient basis, and is generally appropriate in children with grade 2 hypertension and younger www.ah.viamedica.pl children with AH. Diagnostic step 3 includes highly specialized tests reserved for patients in whom the diagnosis has not been established despite completed step 1 and 2 investigations or AH is resistant to treatment. The diagnosis of hypertension in children and adolescents should by confirmed by ABPM. Due to lacking reference values for younger children and the possibility of false positive diagnoses, only children above 5 years of age and/or above 120 cm in height should be routinely referred for ABPM. In younger children, the diagnosis of hypertension is based on office measurements, and ABPM is performed in exceptional, individually qualified cases.
In most children with hypertension, an immediate institution of antihypertensive therapy is not necessary, which usually allows complete diagnostic investigations before the treatment is started. Indications for initiating antihypertensive therapy before completion of the differential diagnosis include high BP values (grade 2 hypertension with clinical symptoms) and/ /or advanced target organ damage and/or symptomatic hypertension. Except for hypertensive urgencies and www.ah.viamedica.pl Table VII . Diagnostic steps in children with hypertension
Investigations Comments
Step 1 • complete blood count, creatinine, sodium, potassium, chloride, calcium, bicarbonate, total cholesterol, triglycerides, cholesterol fractions, uric acid, glucose • urine analysis and urine culture • daily albumin excretion or albumin/creatinine ratio in a spot urine sample • kidney and renal artery Doppler ultrasound • ECG • echocardiography with evaluation of left-ventricular mass and the aortic arch • measurement of carotid intima-media thickness (cIMT) • transfontanellar ultrasound in neonates • ABPM in children > 5 years
Step 1 investigations should be performed in all patients with the diagnosis of hypertension cIMT measurement is optional ABPM is currently widely available; evaluation in children < 6 years has not been validated
Step Oral glucose tolerance test is recommended as mandatory in patients with BMI > 85 th percentile. Fasting insulin allows calculation of HOMA-IR, and insulin in the fasting state and at 120 minutes after glucose administration allows evaluation of the insulin sensitivity index. Multiple measurements during a 240-minute test allow calculation of areas under the glucose and insulin curves and are optional Urinary steroid profile is currently recommended over previously used urinary 17-keto-and 17-hydroxysteroids Measurements of thyroid hormones and vitamin D 3 metabolites in patients with a suspicion of specific pathologies Dynamic scintigraphy is recommended to evaluate renal perfusion, urine excretion, split renal function, and to estimate scarring (static DMSA scintigraphy is more sensitive in detecting scarring but does not allow evaluation of renal perfusion)
Step 3
• non-invasive and invasive renal artery imaging (computed tomography angiography, magnetic resonance angiography, invasive angiography) • diagnostic imaging of adrenal pathology/paraganglioma • non-invasive imaging of other vascular beds (visceral arteries, intracranial arteries) • molecular testing
Step 3 investigations are performed in patients in whom the diagnosis has not been established despite completed step 1 and 2 investigations and/or treatment is unsuccessful ABPM -ambulatory blood pressure monitoring; BMI -body mass index; DMSA -dimercaptosuccinic acid; ECG -electrocardiogram; HOMA-IR -homeostatic model assessment-insulin resistance; cIMT -carotid intima-media thickness emergencies, if pharmacological treatment is necessary before completion of the diagnostic tests, long-acting dihydropyridine calcium antagonists are preferred as this drug class has the least effect on laboratory test findings [43] .
General approach to the treatment of hypertension in children and adolescents
General approach to and indications for the treatment of hypertension in children and adolescents are based on evaluation of the severity of hypertension, its nature (primary versus secondary), and concomitant conditions and target organ damage. Treatment monitoring and modifications based on ABPM are recommended (Figure 1 ). Antihypertensive pharmacological treatment and its success rates depend on the aetiology of hypertension.
Hypertension in chronic kidney disease
In the paediatric population, hypertension secondary to CKD is the major cause of hypertension in younger children, and the major cause of severe hypertension with target organ damage at all ages. Hypertension is present in more than 54% of children with chronic kidney disease. The prevalence of AH increases with decreasing values of glomerular filtration rates (GFR). Hypertension is more common in children with CKD caused by glomerulopathy and practically all who have developed CKD due to haemolytic-uremic syndrome. Hypertension affects up to 80% children on dialysis (stage 5 CKD). The pathogenesis of AH in the course of CKD involves both the renin-dependent and hypervolaemic mechanisms. As GFR decreases, the contribution of sodium and water retention to the pathogenesis www.ah.viamedica.pl of AH in patients with CKD becomes more and more important. Inadequately controlled AH is an important cause of deaths occurring during renal replacement therapy due to cardiovascular complications. Moreover, AH is the primary factor of CKD progression, along with proteinuria. Goals of hypertension treatment in children with chronic kidney disease include both reduction of the risk of future cardiovascular events and delaying progression of chronic kidney disease. According to the ESC and Kidney Disease Improving Global Outcomes (KDIGO) guidelines, the BP threshold for initiating antihypertensive therapy is the 90 th percentile for gender and age. However, in both 2009 and 2016 ESH guidelines the BP threshold at which treatment should be started has been defined ambiguously. Based on randomized prospective studies, clinical observations, expert opinions, and the results of recently published meta-analyses of studies in adults, it should be assumed that antihypertensive treatment should be initiated in children with CKD whose blood pressure values exceed 90 th percentile. It is recommended to monitor antihypertensive treatment by ABPM, and treatment effectiveness should be evaluated bases on the mean 24-hour MAP. Target BP values depend on the severity of proteinuria. Reduction of the mean 24-hour MAP below the 90 th percentile (range 50 th -90 th percentile) is recommended in children with chronic kidney disease without proteinuria or with proteinuria below 0.5 g per day, and in children with proteinuria over 0.5 g per day 24-hour MAP should be lower than the 50 th percentile [44, 45] . However, because there is linear relationship between proteinuria and progression of CKD, it is also recommended to try to lower 24h MAP values below 50 th percentile in all children with CKD if such treatment is well tolerated [24] .
First-line antihypertensive drug classes in children with chronic kidney disease are RAAS inhibitors: angiotensin converting enzyme blockers (ACEI) and angiotensin II type 1 receptor blockers (ARB). This is based on the pathomechanism of hypertension in chronic kidney disease and the published results of clinical trials and observational studies in children. Prospective multicentre studies showed the efficacy and safety of ACEI as antihypertensive and renoprotective drugs (ramipril, enalapril), and similar data were obtained for ARB (losartan) in single-centre studies. In addition, observational studies showed better BP control in children treated with RAAS inhibitors compared to other antihypertensive drug classes. These drugs are not recommended in patients with a very low GFR (< 15-20 mL/min/1.73 m 2 ) due to a risk of significant renal function worsening and/or hyperkalaemia. Dual therapy with ACEI and ARB may result in an additional BP-lowering effect and a reduction of proteinuria. However, such treatment is currently not recommended if additional indications are not present (antiproteinuric effect) due to concerns regarding the safety of such combined treatment. Renin inhibitors were tested in clinical studies in children but their renoprotective effect was not evaluated and these drugs continue not to be licensed for use in children [46] .
Achieving target BP in patients with chronic kidney disease usually requires multiple antihypertensive drugs. Individualization of further pharmacological treatment depending on the clinical scenario is recommended in children. Beta-blockers are the recommended second-line drugs in children with chronic kidney disease due to their additional effect on Dihydropyridine calcium antagonists, previously used as first-line drugs in children with chronic kidney disease, are currently used as further choice drugs in proteinuric patients, due to the fact that they increase proteinuria and hyperfiltration. This negative effect is absent or reduced in combination with RAAS inhibitors [47] .
Hypertension in patients on dialysis therapy
Hypertension in children with CKD requiring renal replacement therapy is found in 55-79% of patients, including 56-79% treated with haemodialysis, 54-75% treated with peritoneal dialysis (in Poland, 56% and 54%, respectively), as well as around 66% of patients after kidney transplantation [48] [49] [50] . It should be noted that approximately 20% of dialyzed children with hypertension are untreated, and among those undergoing treatment, nearly 75% of children have poorly controlled hypertension [48] . Since the assessment of blood pressure measurements performed in Dialysis Wards (before and after haemodialysis) to a lesser extent correlates with left ventricular hypertrophy than 24-hour ABPM in the inter-dialysis period, the diagnosis of AH in children on chronic haemodialysis should be based on 24-hour ABPM in the period between dialysis sessions. The main risk factor for AH in chronically dialysed children is overhydration and excessive salt supply. Other risk factors are: young age of the child (< 6 years), black race, female gender, acquired underlying kidney disease, anaemia and the duration of dialysis therapy (the longer the time, the smaller the percentage of patients with high blood pressure) [48] [49] [50] [51] [52] . The most important element of AH prevention and treatment in children undergoing dialysis is a correct assessment of the hydration status and achieving dry body weight [53] [54] [55] [56] [57] . It is believed that the weight gain between dialysis sessions in children should not exceed 3% of dry body weight. In children on peritoneal dialysis the main cause of hypervolaemia is the so-called latent hypervolaemia associated with uremic cachexia and malnutrition-inflammation-arteriosclerosis syndrome [58] . The volume of residual diuresis plays a significant role in these patients -the higher the residual diuresis, the lower BP values in hypovolaemic hypertensive patients [59] . According to the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKD KDOQI) guidelines published in 2005, target BP values in children requiring chronic renal replacement are < 95 th percentile for sex, age and height [60] . Appropriate dry body weight can be achieved by intensifying dialysis: extending the time of dialysis session to 5-8 hours, performing 4-6 sessions per week, using periodic haemodiafiltration and/or nocturnal dialysis [61, 62] . In patients on peritoneal dialysis, higher ultrafiltration can be achieved by using dialysis fluids with higher osmolality or fluids containing icodextrin [63] . Pharmacological treatment involves the use of dihydropyridine calcium antagonists, ACEI and ARB [64] . There are no explicit recommendations regarding the choice of the drug. It should be remembered, however, that the treatment with ACEI and ARB is associated with the risk of hyperkalaemia.
Renovascular hypertension
Renovascular hypertension is among the major causes of severe hypertension in children and adolescents. The main cause of renovascular hypertension in this age group is FMD, but in 20-40% of cases renovascular hypertension is a complication of other conditions (syndromic renovascular hypertension), including neurofibromatosis type 1 (> 15%) [65] [66] [67] . Renovascular hypertension may also be caused by a congenital or acquired (e.g., transplant renal artery stenosis) stenosis of the main renal artery or additional renal arteries and/or segmental branches [68] [69] .
Investigations for and the diagnosis of renovascular hypertension
The diagnosis of renovascular hypertension is based on a finding of a hemodynamically significant stenosis of one or both renal arteries (Figure 2 ). Invasive angiography, often with selective renal artery catheterization, continues to be a reference method but should be performed only if percutaneous treatment, during the same procedure, is planned based on the results of non-invasive imaging. It should be noted that in children and adolescents with renovascular hypertension, the sensitivity and specificity of non-invasive imaging tests, such as Doppler ultrasound (73%, 83%), nuclear magnetic resonance www.ah.viamedica.pl angiography (80%, 62%) and computed tomography (93%; 81%), are significantly lower than that of the classic arteriography, which is regarded as gold standard method [70] . Routine evaluation of renal vein renin activity or level is not recommended. This test may be performed in case of diagnostic uncertainties.
Scintigraphy is not recommended in AAP guidelines or in clinical guidelines for adult patients, including the guidelines of the Polish Society of Hypertensions, in the diagnostic algorithm for renovascular hypertension in adults [4, 24] . However, in our opinion the assessment of split renal function and analysis of perfusion curves helps in deciding on surgical treatment in difficult cases (young children in whom percutaneous treatment is impossible), allows the evaluation of the treatment effects after interventional procedures (percutaneous treatment/surgery) and is an additional criterion for the diagnosis of hypertensive nephropathy in a kidney with normal renal artery and exposed to high blood pressure before treatment [71] .
Treatment of renovascular hypertension
The ultimate and causative therapy of renovascular hypertension is an interventional treatment that eliminates the underlying cause of hypertension. Although pharmacological treatment allows at least partial BP control, it does not cure the patient. In patients with Takayasu disease, immunosuppressive treatment should be considered as causative therapy, and antihypertensive treatment, including interventional procedures, as treatment of disease complications.
The approach to pharmacological treatment depends on whether unilateral or bilateral RAS is present (Table VIII) . recommendations, prophylactic doses of low-molecular-weight heparin should be given for 1-7 days after the procedure in all cases of renal artery catheterization with PTRA, followed by administration of ASA at 1 mg/kg/day for 3-6 months [72] . Experience with stenting in renovascular hypertension in children and adolescents is relatively limited [73] . Due to ongoing growth, stents mounted on balloon catheters that can be redilated later are recommended. If it is possible to implant a stent with a diameter corresponding to the size of the renal artery in an adult person, a self-expanding stent can be used.
Interventional treatment of renovascular hypertension
Surgery is considered as a last resort in the treatment of renovascular hypertension. Two major approaches to the surgical treatment of renovascular hypertension are revascularization and nephrectomy. Surgical revascularization is indicated if pharmacological therapy and PTRA were unsuccessful, and nephrectomy is indicated for unilateral RAS with severely impaired function of the ischemic kidney, with reduction of size of the ischemic kidney is reduced in size and its relative function has decreased to below 10-15%. In children and adolescents in whom renovascular hypertension is associated with an involvement of visceral vessels and/ /or midaortic syndrome, the therapeutic approach must be planned individually and mostly commonly involves staged procedures, taking into consideration their possible extent, type and sequence, including renal revascularization.
Major surgical techniques used for renal revascularization in adolescents include repair using a prosthetic or autologous patch, and kidney autotransplantation following excision of the stenosed arterial segment.
Hypertension in children after surgical treatment of coarctation of the aorta
Hypertension is an invariable and major symptom of congenital coarctation of the aorta. Following interventional treatment that resulted in a correction of the anatomical stenosis, hypertension persists or develops after a period of normotension in about 32.5% (25-68%) of patients. In a large proportion of patient, exercise-induced hypertension may be diagnosed based on an exercise test [74] [75] [76] [77] .
Treatment of hypertension in children after surgical treatment of coarctation of the aorta
Paediatric studies showed efficacy of ACEI (ramipril), ARB (candesartan), and metoprolol. AHA recommends ARB or ACEI and beta-blockers as first line drugs. Routine annual ABPM and an exercise test every 2 years are recommended by the experts. Abnormal results of these tests are an indication for pharmacological therapy and possible diagnostic investigations for recoarctation. In patients after invasive treatment (surgical or endovascular) of CoA in whom AH is still present or developed after period of normotension, ABPM should be regularly done to assess treatment efficacy. According to the recommendations of both AHA and ESC, the assessment of postoperative anatomy of the aorta, including aortic arch configuration, as factors affecting the recurrence and severity of AH, requires periodic imaging examinations (depending on age ECHO, CT, MRI patient), performed usually every few years [78, 79] . In patients with coarctation of the aorta and coexistence of a bicuspid aortic valve, the monitoring must additionally include the evaluation of anatomy and potential aortic valve dysfunction and the degree of ascending aorta dilatation. In these patients, AH treatment should be particularly aggressive.
Monogenic hypertension
The diagnosis of monogenic hypertension is based on the detection of a typical intermediate phenotype,
www.ah.viamedica.pl which is often possible already during step 1 and 2 investigations. In some cases, a family history of hypertension associated with a typical phenotype or resistant to treatment may be ascertained (Table IX) . The diagnosis of a specific form of the disease usually allows introducing a treatment targeted to the main disorders leading to the development of AH [80] [81] [82] [83] [84] [85] [86] [87] [88] . Diagnosis and treatment of these forms of AH should be carried out in reference centres where molecular diagnostics can be performed.
Primary hypertension
Primary hypertension is the major cause of hypertension in children above 12 years of age, accounting for about 50% of all cases of hypertension in the developmental period. The predominant interme diate phenotype of primary hypertension is abnormal body composition with visceral obesity, abnormal muscle-to-adipose tissue proportion and metabolic disturbances typical for metabolic syndrome (Table X) [89, 90] . Besides the presence of metabolic disorders directly related to visceral obesity, primary hypertension is characterised by the tendency to higher uric acid levels. The risk of target organ damage is related to the degree of metabolic abnormalities and the amount of visceral fat as evaluated by waist circumference.
Non-pharmacological therapy including both dietary modifications and physical activity is of major importance in the management of primary hypertension. Daily high-to moderate-intensity exercise for 60 to 90 minutes is recommended. There are no contraindications to practicing certain types of sport/physical activity. Dietary management is not different from that used in the prevention and treatment of obesity. In addition to the restrictions on the size, composition and caloric content of meals, it is important to drastically limit the intake of table salt, which means essentially eliminating adding salt to foods.
Pharmacological therapy should be considered in children with grade 1 hypertension in whom BP was not adequately lowered despite 6-12 months of non-pharmacological therapy and is indicated in children with grade 2 hypertension and/or target organ damage. Due to concomitant metabolic disturbances and mechanism of action (increase in peripheral vascular resistance), beta-blockers and diuretics are not recommended as first-and second-line drugs, and the preferred drug classes are ACEI, ARB, and dihydropyridine calcium antagonists. In post-pubertal women who do not use contraception, instead of RAAS inhibitors, new generation beta-blockers with vasodilatory properties may be used, as these drugs do not induce adverse metabolic effects and do not increase peripheral vascular resistance, and dihydropyridine calcium antagonists. Due to the fact that the risk of target organ damage is associated with metabolic disturbances and visceral obesity, it is recommended to include regular anthropometric measurements (waist circumference) in addition to evaluation of BP values and target organ damage when monitoring treatment effects [91] .
Hypertension in children with diabetes
Currently, about 205,000 people suffer from type 1 diabetes (T1DM) in Poland, of which more than 20,000 are children and adolescents. In addition, a four-fold increase in the incidence of T1DM has been observed over the past 25 years [92] . With the increase in the prevalence of overweight and obesity, the number of children with type 2 diabetes (T2DM) is also increasing in the Polish population [93] .
Based on the few studies in which the diagnosis was based on a generally accepted paediatric definition, the prevalence of AH in children with T1DM is estimated at 4-7%, whereas this complication is present in as much as 23-40% of paediatric patients with T2DM [94] [95] [96] . In this group of patients there is also a higher prevalence of metabolic disorders and metabolic syndrome, which is related to the pathogenesis of T2DM. Although AH most often affects patients with T2DM, its prevalence in children and adolescents with T1DM becomes increasingly common clinical problem [97, 98] . AH is one of the main risk factors for the development of microand macrovascular complications, cardiovascular disease, and diabetic kidney disease which are the main causes of morbidity and mortality in patients with T1DM and T2DM [99, 100] .
Pathogenesis of hypertension in children with diabetes
The pathogenesis of AH in children with T1DM is not fully understood. Comparison of the clinical picture of children with primary hypertension and children with T1DM and AH indicates the involvement of common pathogenetic mechanisms, such as overweight and obesity, disorders of body fat distribution, and associated insulin resistance. Poor diabetes control and use of higher doses of insulin are also significant factors [101] . As in the general population, in children with T1DM significant increase in AH incidence is observed from puberty and on.
www.ah.viamedica.pl In patients with T1DM, abnormal circadian BP pattern, including non-dipping (lack of nocturnal BP drop) and significant morning BP surge is observed on early stage of disease. The association of elevated BP and abnormal circadian BP pattern with early markers of kidney damage suggests the involvement of both renal mechanisms and central regulation of arterial pressure [102] [103] [104] [105] . The metabolic disorders resulting from chronic hyperglycaemia leading to atherosclerosis and increased arterial stiffness are also involved in the development of hypertension in diabetic patients [106] [107] [108] [109] . Although, renal failure in diabetic kidney disease usually occurs after many years of disease, the early stages of diabetic kidney disease characterized by increased albuminuria are observed also in the paediatric population [110] [111] [112] [113] . In adolescents kidney damage in T1DM is directly related to elevated BP values, and effective antihypertensive treatment slows the progression of kidney damage [114] .
In children and adolescents with T2DM, AH is detected at diagnosis of diabetes in 12-25% of patients and is associated with disorders resulting from insulin resistance and abdominal obesity [115, 116] . Moreover, patients with T2DM are more frequently affected by atherogenic dyslipidaemia leading to early presence of increased vascular stiffness [117] , and in those with significant obesity, kidney damage occurs before clinically overt T2DM. In some patients increased urinary albumin excretion is found at diagnosis. Due to the fact that in T2DM patients hypertension coexists with other features of the metabolic syndrome, these patients more frequently and earlier develop cardiovascular disease and nephropathy than those with T1DM. For this reason, patients with T2DM need comprehensive treatment for all disorders associated with the metabolic syndrome [118] .
diagnostic investigations for hypertension in children with diabetes
Blood pressure measurements in children and adolescents with diabetes should be performed on each visit. In children below 7 years of age BP should be measured at least twice a year [119] . In adolescents over 12 years of age with T1DM, values above 95 th percentile, or above 130/80 mmHg are considered to be abnormal blood pressure regardless of the 95 th percentile. 24-hour ABPM should be used to confirm the diagnosis of AH.
Due to the fact that children with diabetes are at increased risk of developing cardiovascular disease, a blood pressure reduction of ≤ 90 th percentile for age, sex and height or to ≤ 120/80 mmHg is recommended regardless of age.
Lowering blood pressure leads to regression of organ damage, but too intensive treatment and lowering of diastolic pressure < 60 mmHg may impair coronary artery flow [120] . Diagnostic investigations for secondary AH in diabetic child should be performed according to the principles outlined earlier.
Diagnostic investigations for secondary AH should be performed according to the principles outlined earlier.
Treatment of hypertension in in patients with diabetes
The treatment of AH in paediatric patients should include lifestyle modification, adequate metabolic control of diabetes and pharmacological therapy. The non-pharmacological treatment including body mass normalization (BMI < 90 th percentile for sex and age), regular physical activity (moderate to intense > 1 hour per day) and low sodium diet is of key importance (Table XI) .
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For pharmacological therapy, the recommended antihypertensive drug classes are ACEI [121] or, in case of ACEI intolerance, ARB. Pharmacological treatment should be monitored by HBPM and ABPM, and the nocturnal BP fall should be taken into consideration.
Drug classes recommended for the treatment in children and adolescents with hypertension and diabetes are ACEI [122] and, in case of ACEI intolerance, ARB. Antihypertensive treatment in children with diabetes is synonymous with renoprotective treatment and is based on similar principles. Effective pharmacotherapy in patients with diabetic nephropathy delays the development of end-stage renal failure [122] . Treatment with ACEI in adolescents is associated with long-term therapy, which can cause many adverse effects, such as cough, hyperkalaemia, headaches, impotence and the risk of pseudoallergic reactions. It should be remembered that ACEI may cause serious foetal complications, which is a significant potential problem when treating teenage girls [123] .
In one-third of patients with T2DM, monotherapy with ACEI or ARB is ineffective [116] . These patients require combination therapy (second line drugs are dihydropyridine calcium antagonists, followed by vasodilating beta-blockers and thiazide diuretics)
Hypertensive urgencies and emergencies
In the developmental period, hypertensive emergencies are virtually always caused by secondary hypertension, including those casued to acute kidney disease (acute glomerulonephritis, haemolytic-uremic syndrome). Hypertensive urgencies associated with acute BP increases are also seen in children with primary hypertension. The choice of intravenous drug depends on the aet iology of hypertension. Intravenous medications are used for the treatment of hypertensive emergencies, with the choice of the drug based on the aetiology of hypertension. In hypertensive emergencies, administration of an intravenous beta-blocker (labetalol, esmolol) and a peripheral vasodilating agent (hydralazine, sodium nitroprusside, or nitroglycerine) is recommended. Due to fluid retention caused by peripheral vasodilation during prolonged therapy, an addition of a diuretic is also recommended. Oral treatment is initiated upon improvement of the general clinical condition of the patient. In hypertensive crises due to acute or chronic kidney disease (patients on dialysis therapy), volume control and removal of excess fluid by dialysis, or using diuretics in patients with preserved glomerular filtration, is of major importance. Addition of a RAAS inhibitor is recommended in hypertensive emergencies due to microangiopathy. In hypertensive urgencies, oral treatment is usually possible. BP should be lowered by 30% of the overall Figure 3 , and dosage of the drugs used in hypertensive emergencies, along with their adverse effects and contraindications, is summarized in Table  XII and XIII. In children with hypertensive urgencies and acute BP rises who may be treated with oral medications, rapidly acting drugs are recommended, followed by the institution of long-term antihypertensive therapy [124] (Table XIV) . Other selected forms of hypertension are presented in Table XV .
Neonatal hypertension
The incidence of AH in neonates is approximately 0.2-0.3% [125, 126] , but it is much higher (0.81-9%) in premature infants and in the presence of additional risk factors (umbilical vessel catheterization, patent ductus arteriosus, intraventricular haemorrhage) and associated diseases (40% in neonates with chronic bronchopulmonary disease). Neonatal hypertension is a secondary nature and is related mainly to renal pathology, most commonly renovascular diseases, but iatrogenic factors are also of major importance [127] .
Despite multiple data on reference BP values in neonates depending on specific measurement techniques, the definition of hypertension is still based on the percentile values reported in the Report of the Second Task Force on Blood Pressure Control (1986) in Children and derived from BP measurements using a mercury sphygmomanometer (Table  XVI) . According to the 1986 Report of the Second Task Force, hypertension may be diagnosed in neonates when SBP values above the 95 th percentile for chronological age are found on three occasions. In preterm infants, SBP values should be referred to gestational age [125, 127] . Despite many methodological reservations and the fact that currently almost exclusively oscillometric measurements are used, the reference values given in the 2 nd Report are practical and easy to apply. Table XVII shows a compilation of previous reference BP values that summarizes the 95 th and 99 th SBP, DBP, and MAP percentiles in 2-week-old neonates, depending on gestational age [129] .
Due to high rates of unreliable findings, including false positive results (up to 41% in children below 12 months of age), and resulting exposure to unnecessary investigations and treatment, BP measurement in healthy neonates is not recommended. Indications for BP measurement and investigations for hypertension concern preterm neonates born with concomitant congenital malformations and diseases associated with hypertension and newborns requiring hospitalization. It is recommended to perform BP measurements in appropriate www.ah.viamedica.pl [126] conditions and using the technique described in Table XVIII [129] [130] [131] [132] [133] [134] [135] . In neonates, infants and young children, auscultatory measurement is not recommended due to technical difficulties and a high prevalence of the white coat effect compared to automatic measurement. The BP measurement using the automatic oscillometric method is fraught with the risk of erroneous detection of elevated blood pressure values in the first measurement. In the case of indications for BP measurement in these age groups, if the result of the first measurement is incorrect, it is recommended to perform multiple consecutive measurements in short intervals (using automatic method).
The approach to the differential diagnosis of hypertension and the assessment of target organ damage in neonates does not differ from that in older age groups [135, 136] (Table XIX) .
Treatment of neonatal hypertension
Given the lack of long-term randomized studies to evaluate outcomes of antihypertensive therapy in neonates, most recommendations are expert opinions based on clinical experience. It is not recommended to initiate treatment in asymptomatic neonates with BP values between the 95 th and 99 th percentile [137] . Initiation of pharmacological treatment is justified when BP values are above the 99 th percentile, or target organ damage is present with BP values above the 95 th percentile [138] . The general rule of pharmacological treatment in newborns and infants is to choose medications depending on the potential aetiology of hypertension and the presence of concomitant abnormalities, and the treatment should be started with as low doses as possible. The safest approach is to use short-acting intravenous drugs (Table XX) . Oral antihypertensive therapy is reserved for neonates in a good overall clinical condition (Table XXI) .
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Screening for hypertension in post-hospital care in children born prematurely (≤ 33 weeks of gestation)
These guidelines adopted the management principles published in 2018 by the Polish Neonatological Society and concerning post-hospital care for children born prematurely [5] as well as the Low Birth Weight and Nephron Number Working Group published in 2017 [139] . Children diagnosed with AH before discharge from the neonatal unit should be consulted and provided with specialist care in the paediatric hypertension centre during the hospitalization. Further diagnostic and therapeutic management should be based on the current paediatric guidelines of the Polish Society of Hypertension, the Children's Memorial Health Institute and the European Society of Hypertension.
www.ah.viamedica.pl Children with concomitant kidney and urinary tract pathology should be provided with specialist care in the nephrology, hypertension and paediatric urology centres. This will allow early planning of both treatment of urinary tract defect and renoprotective therapy.
In children in whom normal BP was detected discharge from the neonatal unit, BP should be measured at each medical visit. Automatic measurement on the right arm is recommended as the basic method of BP measurement In children younger than 3 years. If elevated blood pressure values are found, it should be confirmed by auscultatory measurement. The finding of hypertension is an indication to refer the child to the paediatric hypertensive centre.
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